WO2022038955A1 - Composition d'agent d'inactivation de virus procédé d'amélioration de l'efficacité d'inactivation de virus et procédé d'inactivation virale - Google Patents

Composition d'agent d'inactivation de virus procédé d'amélioration de l'efficacité d'inactivation de virus et procédé d'inactivation virale Download PDF

Info

Publication number
WO2022038955A1
WO2022038955A1 PCT/JP2021/027348 JP2021027348W WO2022038955A1 WO 2022038955 A1 WO2022038955 A1 WO 2022038955A1 JP 2021027348 W JP2021027348 W JP 2021027348W WO 2022038955 A1 WO2022038955 A1 WO 2022038955A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
mass
virus inactivating
agent composition
component
Prior art date
Application number
PCT/JP2021/027348
Other languages
English (en)
Japanese (ja)
Inventor
裕之 小野寺
由美子 市村
幸治 中山
Original Assignee
大日本除蟲菊株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大日本除蟲菊株式会社 filed Critical 大日本除蟲菊株式会社
Priority to CN202180058669.4A priority Critical patent/CN116056570A/zh
Priority to JP2022543335A priority patent/JPWO2022038955A1/ja
Publication of WO2022038955A1 publication Critical patent/WO2022038955A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/12—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
    • A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
    • A01N47/44—Guanidine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Patent Document 5 1,4-bis (3,3'-(1-decylpyridinium) methyloxy) butane dibromide and found that this compound is also specifically effective against norovirus.
  • Patent Document 5 the norovirus inactivating agent of Patent Document 5 is excellent, there is still room for study to improve its performance in terms of its rapid effect on virus inactivation.
  • the cationic virus inactivating component is a dialkyldimethylammonium salt (however, the alkyl group is the same or different, and the direct number of carbon atoms is 8 to 20. (Representing a chain saturated hydrocarbon), trialkyl (3-triethoxysilylpropyl) ammonium salt (provided that the alkyl groups are the same or different and represent a linear saturated hydrocarbon having 1 to 18 carbon atoms), 1.
  • the present invention is characterized in that (c) ethanol is blended in an amount of 10% by mass to 80% by mass in the virus inactivating agent composition having the above constitution.
  • the present invention is characterized in that, in the virus inactivating agent composition having the above constitution, the blending amount of (c) ethanol is 35% by mass to 65% by mass.
  • the compounding mass ratio (a) / (b) of the (b) virus inactivating efficacy enhancing component to the (a) virus inactivating component is determined. , 0.001 ⁇ (a) / (b) ⁇ 250.
  • the present invention comprises (a) a virus inactivating agent composition containing 0.01% by mass to 5.0% by mass of a cationic virus inactivating component and water as a virus inactivating component.
  • a virus inactivating efficacy enhancing component one or more selected from the group consisting of 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid, and citric acid. It is a method for enhancing virus inactivating efficacy, which is characterized by addition.
  • the present invention is also a method for inactivating a non-enveloped virus in which the virus inactivating agent composition having the above constitution is brought into contact with the non-enveloped virus.
  • a cationic virus inactivating component of 0.01% by mass to 5.0% by mass as a virus inactivating component, and (b) a virus inactivating effect.
  • a virus inactivating agent composition is excellent in usability without fear of irritation due to alkali to the skin and has excellent rapid effect in virus inactivation.
  • the cationic virus inactivating component is a dialkyldimethylammonium salt (however, the alkyl group is the same or the same or Unlike each other, it represents a linear saturated hydrocarbon having 8 to 20 carbon atoms) and a trialkyl (3-triethoxysilylpropyl) ammonium salt (provided that the alkyl groups are the same or different from each other and have 1 to 18 carbon atoms.
  • virus inactivating agent composition capable of more effectively improving the rapid effect in virus inactivation can be obtained.
  • the cationic virus inactivating component is 1,4-bis (3,3'-(1). -Decilpyridinium) Methyloxy) Butane dibromide, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, chlorhexidine gluconate, and octadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride.
  • a virus inactivating agent composition capable of more effectively improving the rapid effect in virus inactivation can be obtained.
  • the amount of (c) ethanol blended is 35% by mass to 65% by mass, so that the virus A virus with excellent quick-drying properties can be more effectively improved in inactivation, less likely to cause skin irritation during use, and effectively improve the volatilization of the virus inactivating agent composition. It becomes an inactivating agent composition.
  • the virus inactivating agent composition having the configuration of any one of the first to fifth above, (a) the virus is inactive against the virus inactivating component (b).
  • the compounding mass ratio (a) / (b) of the compounding efficacy enhancing component is 0.001 ⁇ (a) / (b) ⁇ 250, the rapid effect in virus inactivation can be further improved.
  • the virus inactivating component contains 0.01% by mass to 5.0% by mass of a cationic virus inactivating component and water.
  • the virus inactivating agent composition is selected from the group consisting of (b) 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid, and citric acid as a virus inactivating efficacy enhancing component.
  • the (a) cationic virus inactivating component compounded as a virus inactivating component in the virus inactivating agent composition of the present invention has a high virus inactivating effect, but is virus inactivating. There was room for consideration in the rapid effect on activation.
  • a cationic virus inactivating component in combination with one or more selected from the group consisting of fumaric acid, phosphoric acid, lactic acid, and citric acid, in virus inactivation. It is the first finding by the present inventors that the rapid effect could be improved synergistically.
  • an organic acid and / or an inorganic acid which is a virus inactivating efficacy enhancing component is a virus inactivating agent. It is blended in an amount of 0.02% by mass or more and 10.0% by mass or less with respect to the composition, preferably 0.03% by mass or more and 5.0% by mass or less, and 0.10% by mass or more and 2.0% by mass or less. The following is more preferable.
  • any of anionic surfactant, nonionic surfactant and amphoteric surfactant is preferably used.
  • the blending amount of the surfactant in the virus inactivating agent composition of the present invention is not particularly limited, but is preferably 0.1% by mass or more and 10% by mass or less.
  • the cationic virus inactivating component contained in the virus inactivating agent composition of the present invention is not included in the surfactant in the present specification.
  • anionic surfactants include fatty acid soaps, alkylbenzene sulfonates, linear alkylbenzene sulfonates, alkyl sulfates, ⁇ -olefin sulfonates, alkyl phosphate ester salts, polyoxyethylene alkyl ether sulfates, etc. Examples thereof include polyoxyethylene alkyl phenyl ether sulfate and polyoxyethylene alkyl ether phosphate.
  • nonionic surfactants include polyoxyethylene alkyl ethers, polyoxyethylene alkyl phenyl ethers, polyoxyethylene higher fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene glycerin fatty acid esters, and polyoxyethylene hydrogenated castor oil. , Palm oil fatty acid diethanolamide, polyoxyethylene polyoxypropylene alkyl ether, fatty acid alkanolamide, alkylamine oxide and the like.
  • amphoteric surfactants include betaine-type surfactants. Specific examples thereof include lauryl-N, N-dimethylacetate betaine, laurylamide propyl-N, N-dimethylacetate betaine, coconut alkylamide propyl-N, N-dimethylhydroxypropyl sulfobetaine and the like.
  • the virus inactivating agent composition of the present invention is an aqueous type, and water is mainly used as the solvent.
  • water examples include purified water such as ion-exchanged water and reverse osmosis membrane water, ordinary tap water, industrial water, and deep ocean water.
  • virus inactivating agent composition of the present invention as other components, as necessary, antibacterial agents other than cationic virus inactivating components, virus inactivating agents, algae-proofing agents, rust-preventing agents, etc.
  • a solvent, a chelating agent, a fragrance, a deodorant component, a pH adjuster, a moisturizing component, a thickener, etc. within a range that does not impair the effects of the present invention, an antibacterial effect, a virus inactivating effect, an algae-proofing effect, etc.
  • Anti-corrosion effect, cleaning effect, fragrance, deodorant property, moisturizing effect, thickening effect and the like may be imparted.
  • the solvent examples include normal paraffin, isoparaffin, liquid paraffin, naphthenic hydrocarbon, vaseline, squalane, hydrocarbon solvent such as ⁇ -olefin oligomer, 1-propanol, 2-propanol (IPA), 1-butanol, 2 -Alcohol solvents such as butanol, tertiary butanol, 1-pentanol, 1-hexanol, benzyl alcohol, 2-phenylethanol, 2-phenoxyethanol (ethylene glycol monophenyl ether), ethylene glycol, propylene glycol, 1-phenoxy-
  • glycol-based solvents such as 2-propanol (propylene glycol phenyl ether), 1,3-butylene glycol, propylene glycol monobutyl ether, dipropylene glycol monobutyl ether, and tripropylene glycol monobutyl ether.
  • fragrances include limonene such as d-lymonen, pinen such as ⁇ -pinen and ⁇ -pinen, simen such as p-simene, hydrocarbon fragrances such as inden and cariophyllene, linalol, geraniol, citronellol, and l-menthol.
  • Vanillin, Ethylvanylin and other phenolic fragrances octanal, nonanal, undecylaldehyde, undecanal, decylaldehyde, n-butylaldehyde, isobutylaldehyde, hexylaldehyde, citral, terpineol, benzaldehyde, cinnamic aldehyde, anisaldehyde, cumin Aldehyde-based fragrances such as aldehydes, adxal, amilcinnamic aldehydes, and cyclamen aldehydes, muskketones, carboxylics, mentons, cerebral brains, camphor, acetophenone, butyrophenone, tonalide, ⁇ -ionone, ⁇ -ionone, ⁇ -methylionone, ⁇ -methylionone, ⁇ -Ketone-
  • deodorant components include sugar cane extract, green tea extract, cha dry distillate, persimmon extract, grapefruit extract, mozochiku extract, yuzu seed extract, and lotus extract, but in addition to the deodorizing effect. Therefore, sugar cane extract is suitable from the viewpoint of promoting the inactivating action of norovirus.
  • pH adjuster examples include other organic acids such as acetic acid, malic acid and salicylic acid, other inorganic acids such as hydrochloric acid, sodium citrate, sodium carbonate, sodium hydrogencarbonate, sodium hydroxide and the like.
  • moisturizing ingredients include glycols such as glycerin, propylene glycol and 1,3-butylene glycol, and polyhydric alcohols such as sorbitol.
  • thickeners examples include carboxyvinyl polymers, which are cross-linked polyacrylic acids, cellulose derivatives such as carboxymethyl cellulose, hydroxyethyl cellulose, and hydroxypupyl cellulose, xanthan gum, guar gum, arabic gum, sodium alginate, propylene glycol alginate, and ethyl cellulose. , Sodium polyacrylate, cyclodextrin and the like.
  • the virus inactivating agent composition of the present invention thus obtained is applied or sprayed to a place touched by a virus-infected person, a place where a virus-infected person's vomit is treated, or a place contaminated with a virus such as clothes. Therefore, the virus can be effectively removed.
  • the virus adhering to the fingers or the like can be effectively removed and the fingers or the like can be disinfected.
  • the virus inactivating composition of the present invention is highly resistant to enveloped viruses such as influenza virus, coronavirus and herpesvirus, as well as non-enveloped viruses such as norovirus, rotavirus, rhinovirus and adenovirus. Has an activating effect. Therefore, it can also be suitably used for inactivating norovirus, which was difficult to inactivate with conventional virus removing agents.
  • test virus solution 0.1 mL was added and mixed with 0.9 mL of the test solutions of the present inventions 1 to 10 and Comparative Examples 1 to 6 prepared in Example 1 to prepare an action solution. After 1 minute, the working solution was diluted 100-fold with MEM medium to prepare a 10-fold dilution series. The same operation was performed using a phosphate buffered saline solution to which the test virus solution was added as a control.
  • Comparative Examples 5 and 6 containing only the component (a) and Comparative Examples 1 to 3 containing only the component (b) were against feline calicivirus. Therefore, the reduction value of the infectious titer log was smaller than 1.5, and a sufficient virus inactivating effect was not observed. Further, in Comparative Example 4 in which the component (a) was replaced with the cationic virus inactivating component and isopropylmethylphenol, which is another virus inactivating component, was used, the component (b) was used in combination for immediate effect. No virus inactivating effect was obtained, and no enhancing effect was observed in the component (b).
  • the infectious titer logarithmic reduction value was 3.0. It was confirmed that a faster-acting virus inactivating effect could be obtained.
  • test virus solution 0.1 mL was added and mixed with 0.9 mL of the test solution of the present invention 12 prepared in Example 1 to prepare an action solution. After 3 minutes, the working solution was diluted 100-fold with MEM medium to stop the action, and the virus infectious titer was measured as the stock solution of the sample for infectious titer measurement. The same operation was performed using a phosphate buffered saline solution to which the test virus solution was added as a control.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition d'agent d'inactivation de virus caractérisée par le mélange de (a) 0,01 % en masse à 5,0 % en masse d'un composant d'inactivation de virus cationique en tant que composant d'inactivation de virus, (b) 0,02 % en masse à 10,0 % en masse d'un, de deux ou de davantage de composants choisis dans le groupe constitué par l'acide fumarique, l'acide phosphorique, l'acide lactique et l'acide citrique, en tant que composants améliorant l'efficacité d'inactivation de virus, et de l'eau.
PCT/JP2021/027348 2020-08-20 2021-07-21 Composition d'agent d'inactivation de virus procédé d'amélioration de l'efficacité d'inactivation de virus et procédé d'inactivation virale WO2022038955A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202180058669.4A CN116056570A (zh) 2020-08-20 2021-07-21 病毒灭活剂组合物及病毒灭活效力增强方法、以及病毒灭活方法
JP2022543335A JPWO2022038955A1 (fr) 2020-08-20 2021-07-21

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-139320 2020-08-20
JP2020139320 2020-08-20

Publications (1)

Publication Number Publication Date
WO2022038955A1 true WO2022038955A1 (fr) 2022-02-24

Family

ID=80350349

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/027348 WO2022038955A1 (fr) 2020-08-20 2021-07-21 Composition d'agent d'inactivation de virus procédé d'amélioration de l'efficacité d'inactivation de virus et procédé d'inactivation virale

Country Status (3)

Country Link
JP (1) JPWO2022038955A1 (fr)
CN (1) CN116056570A (fr)
WO (1) WO2022038955A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115839522A (zh) * 2022-11-01 2023-03-24 光谷洁净(武汉)科技有限公司 一种高效低阻空气过滤器

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009526060A (ja) * 2006-02-09 2009-07-16 ゴジョ・インダストリーズ・インコーポレイテッド 抗ウイルス法
US20090232748A1 (en) * 2003-11-07 2009-09-17 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
JP2010195782A (ja) * 2002-05-29 2010-09-09 L'air Liquide Sante Internatl Ｂ型肝炎ウイルスに対する活性を有する殺菌剤
CN106577756A (zh) * 2016-11-28 2017-04-26 青岛源之林农业科技开发有限公司 一种流感病毒消毒液
JP2017528463A (ja) * 2014-09-09 2017-09-28 ロンザ インコーポレーテッド 四級アンモニウム化合物を含有する消毒組成物
JP2018090564A (ja) * 2016-11-30 2018-06-14 株式会社Adeka 清掃用シート
JP2019532024A (ja) * 2016-08-11 2019-11-07 エコラボ ユーエスエー インコーポレイティド 抗微生物第４級化合物とアニオン性界面活性剤との間の相互作用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2471559T3 (en) * 2006-02-09 2015-01-12 Gojo Ind Inc Antiviral method
US8119115B2 (en) * 2006-02-09 2012-02-21 Gojo Industries, Inc. Antiviral method
KR101649387B1 (ko) * 2008-12-25 2016-08-18 고쿠리츠다이가쿠호진 히로시마다이가쿠 규소함유 화합물을 포함하는 항균제 조성물 및 항바이러스 조성물, 및 항균화 방법, 세정 및 구강세정 방법, 항균제 및 항바이러스제 고정화 방법
EP2672828B1 (fr) * 2011-02-10 2015-04-29 Unilever N.V. Composition antimicrobienne

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010195782A (ja) * 2002-05-29 2010-09-09 L'air Liquide Sante Internatl Ｂ型肝炎ウイルスに対する活性を有する殺菌剤
US20090232748A1 (en) * 2003-11-07 2009-09-17 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
JP2009526060A (ja) * 2006-02-09 2009-07-16 ゴジョ・インダストリーズ・インコーポレイテッド 抗ウイルス法
JP2017528463A (ja) * 2014-09-09 2017-09-28 ロンザ インコーポレーテッド 四級アンモニウム化合物を含有する消毒組成物
JP2019532024A (ja) * 2016-08-11 2019-11-07 エコラボ ユーエスエー インコーポレイティド 抗微生物第４級化合物とアニオン性界面活性剤との間の相互作用
CN106577756A (zh) * 2016-11-28 2017-04-26 青岛源之林农业科技开发有限公司 一种流感病毒消毒液
JP2018090564A (ja) * 2016-11-30 2018-06-14 株式会社Adeka 清掃用シート

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115839522A (zh) * 2022-11-01 2023-03-24 光谷洁净(武汉)科技有限公司 一种高效低阻空气过滤器
CN115839522B (zh) * 2022-11-01 2023-08-25 光谷洁净(武汉)科技有限公司 一种高效低阻空气过滤器

Also Published As

Publication number Publication date
JPWO2022038955A1 (fr) 2022-02-24
CN116056570A (zh) 2023-05-02

Similar Documents

Publication Publication Date Title
JP5925758B2 (ja) 抗菌性組成物
JP5554926B2 (ja) 抗ウイルス法
JP5788385B2 (ja) 抗菌性組成物
EP2672828B1 (fr) Composition antimicrobienne
CA2666146A1 (fr) Procedes d'inactivation de virus
JP2013506650A (ja) サニタイジング組成物
JP6783516B2 (ja) カリシウイルス不活化効果を有する組成物
JP6704099B1 (ja) 殺菌またはウイルス不活性化剤組成物、および殺菌またはウイルス不活性化効力増強方法
WO2022038955A1 (fr) Composition d'agent d'inactivation de virus procédé d'amélioration de l'efficacité d'inactivation de virus et procédé d'inactivation virale
JP2018080126A (ja) ベシウイルス属ウイルス及び／又はノロウイルス属ウイルス用ウイルス不活性化剤及び衛生資材
WO2022038630A1 (fr) Composition de nettoyage de surface et son utilisation
TW202044992A (zh) 殺菌或病毒不活性化劑組成物，及增強殺菌或病毒不活性化效力之方法
JP2022125090A (ja) ウイルス不活性化組成物
WO2021095636A1 (fr) Composition d'agent d'inactivation de virus et procédé d'amélioration de l'efficacité d'inactivation de virus, et procédé d'inactivation de virus
TWI841480B (zh) 病毒去活化劑組成物及增加病毒去活化效能之方法，以及病毒去活化之方法
JP2019531324A5 (fr)
JP2010285387A (ja) ノロウイルス不活性化剤
JP2016117693A (ja) 抗菌性、抗ウイルス性を有する水溶性組成物
CN109362768A (zh) 一种含矿物盐的消毒喷雾
JP2018197205A (ja) ウイルス不活性化剤、ノロウイルス不活性化剤及び衛生資材
JP2011073982A (ja) 配合組成物
JP2023017494A (ja) 皮膚を菌又はウイルスから防御する方法
JP2023017691A (ja) 容器詰液状組成物
JP2022056421A (ja) 抗ウイルス剤、消毒剤及び洗浄剤
CN115279185A (zh) 胶束消毒剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21858104

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022543335

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21858104

Country of ref document: EP

Kind code of ref document: A1